NCT05743595 — Washington University School of Medicine neoantigen vaccine trial
Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Registry record
| Registry ID | NCT05743595 ↗ |
|---|---|
| Lead sponsor | Washington University School of Medicine |
| Collaborators | Incyte Corporation, PapiVax Biotech, Inc., The Foundation for Barnes-Jewish Hospital |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Unmethylated Glioblastoma |
| Enrollment | 27 participants (target) |
| Start date | 2023-10-27 |
| Primary completion | 2026-04-07 |
| Last registry update | 4 May 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05743595), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT05743595?
NCT05743595 (Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma) is registered on ClinicalTrials.gov as Phase 1, sponsored by Washington University School of Medicine.
Is NCT05743595 recruiting?
As of the 2026-05-04 registry update, NCT05743595 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05743595?
The lead sponsor is Washington University School of Medicine. Collaborators: Incyte Corporation, PapiVax Biotech, Inc., The Foundation for Barnes-Jewish Hospital.
What condition does NCT05743595 study?
The registered condition is Unmethylated Glioblastoma. Primary completion is listed as 2026-04-07.
Are results available for NCT05743595?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05743595.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.